DB959
As of the edition of 20 October 2026, DB959 is a drug: in active development; acts on PPARD and PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Unknown
- Registered trials
- 3, 0 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| T3D Therapeutics | Lead sponsor of trials | 2015 to now |